Does Rallies track congressional trades in TNDM?

Yes. Rallies tracks politician and congressional stock disclosures for TNDM, including reported purchases, sales, dates, owners, and trade amounts when available.

Is TNDM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TNDM. It does not provide personalized investment advice.

TNDM (Tandem Diabetes Care, Inc.) Stock Analysis - Politician Trades

Tandem Diabetes Care, Inc. (TNDM) is a publicly traded Healthcare sector company. As of May 21, 2026, TNDM trades at $14.89 with a market cap of $927.20M and a P/E ratio of -10.46. TNDM moved +8.51% today. Year to date, TNDM is -35.03%; over the trailing twelve months it is -36.05%. Its 52-week range spans $9.98 to $45.28. Analyst consensus is buy with an average price target of $30.76. Rallies surfaces TNDM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded TNDM stock?

Recent politician trading activity in TNDM includes disclosures from Josh Gottheimer, Josh Gottheimer, Gil Cisneros, and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

TNDM Key Metrics

Key financial metrics for TNDM
Metric	Value
Price	$14.89
Market Cap	$927.20M
P/E Ratio	-10.46
EPS	$-1.40
Dividend Yield	0.00%
52-Week High	$45.28
52-Week Low	$9.98
Volume	2.82K
Avg Volume	0
Revenue (TTM)	$1.03B
Net Income	$-94.55M
Gross Margin	54.93%

Congressional Trades in TNDM

Josh Gottheimer purchase TNDM on Sep 22, 2025 (amount: $15.00K) for Joint.
Josh Gottheimer sale TNDM on Mar 19, 2025 (amount: $15.00K) for Joint.
Gil Cisneros purchase TNDM on Mar 4, 2025 (amount: $15.00K).
Josh Gottheimer purchase TNDM on Aug 5, 2024 (amount: $15.00K) for Joint.

Latest TNDM News

Tandem Diabetes Care Exceeds $1B Sales, Prepares Three New Pump Launches — Mar 3, 2026
Tandem Posts 58% Q4 Margin, Eyes Pharmacy Shift with $70–80M Headwind and “Toby” FDA Bid — Mar 2, 2026
Tandem Diabetes Upsizes $265M Convertible Notes at 37.5% Premium — Feb 25, 2026
Brown Capital Exits Tandem Diabetes Care Despite $290M Q4 Sales and 15% Growth — Feb 23, 2026
Tandem Diabetes Q4 Sales Rise 15% to $290.4M Drives 30% Stock Rally — Feb 20, 2026

Recent TNDM Insider Trades

Novara Mark David sold 187 (~$4.31K) on Mar 17, 2026.
Novara Mark David sold 2 (~$45.62) on Mar 5, 2026.
Sheridan John F bought 10.00K (~$102.32K) on Aug 11, 2025.

TNDM Analyst Consensus

18 analysts cover TNDM: 0 strong buy, 9 buy, 9 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.76.

Common questions about TNDM

Which politicians traded TNDM stock?: Recent politician trading activity in TNDM includes disclosures from Josh Gottheimer, Josh Gottheimer, Gil Cisneros, and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in TNDM?: Yes. Rallies tracks politician and congressional stock disclosures for TNDM, including reported purchases, sales, dates, owners, and trade amounts when available.
Is TNDM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TNDM. It does not provide personalized investment advice.